Suvecaltamide
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Suvecaltamide
- Molecular weight
- 380.41
- Structure (SMILES)
- CC(C)c1ccc(CC(=O)N[C@H](C)c2ccc(OCC(F)(F)F)cn2)cc1
- 4 1 methylethyl n 1r 1 5 2 2 2 trifluoroethoxy 2 pyridinyl ethyl benzeneacetamide
- 4-(1-METHYLETHYL)-N-((1R)-1-(5-(2,2,2-TRIFLUOROETHOXY)-2-PYRIDINYL)ETHYL)BENZENEACETAMIDE
- cx 8998
- Cx-8998
- CX-8998
- jzp 385
- JZP-385
- jzp385
- JZP385
- mk 8998
- Mk-8998
- MK-8998
- suvecaltamide
- Suvecaltamide
- suvecaltamide [INN]
- SUVECALTAMIDE [USAN]
- Suvecaltamide [WHO-DD]
- suvecaltamide inn
- suvecaltamide usan
- suvecaltamide who dd
- CAS registry numbers
- 953778-58-0
- ChEMBL ID
- CHEMBL1684950
- InChIKey
- IQIKXZMPPBEWAD-CQSZACIVSA-N
- PubChem compound IDs
- 24765479
- FDA ingredient codes (UNII)
- MIA4WMP8QN
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- suvecaltamide
- Type
- Synthetic organic
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- Cav3.1
- Gene symbol
- CACNA1G
- Protein identifier
- O43497
- Median affinity
- 8.92
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- Cav3.2
- Gene symbol
- CACNA1H
- Protein identifier
- O95180
- Median affinity
- 8.09
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- Cav3.3
- Gene symbol
- CACNA1I
- Protein identifier
- Q9P0X4
- Median affinity
- 8.82
- Affinity units
- pIC50
- Mechanism
- Voltage-gated T-type calcium channel modulator
- Action type
- MODULATOR
- Target
- Voltage-gated T-type calcium channel
- Protein identifier
- O43497
- Mechanism
- Voltage-gated T-type calcium channel modulator
- Action type
- MODULATOR
- Target
- Voltage-gated T-type calcium channel
- Protein identifier
- O95180
- Mechanism
- Voltage-gated T-type calcium channel modulator
- Action type
- MODULATOR
- Target
- Voltage-gated T-type calcium channel
- Protein identifier
- Q9P0X4
Open Targets mechanisms
- Mechanism
- Voltage-gated T-type calcium channel modulator
- Action type
- MODULATOR
- Target
- Voltage-gated T-type calcium channel
- Condition
- Epilepsy
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000474
- Subject identifier
- D004827
- Condition
- Essential Tremor
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003108
- Subject identifier
- D020329
- Condition
- Schizophrenia
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005090
- Subject identifier
- D012559
- Condition identifier
- EFO_0000474
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003108
- Highest recorded phase
- 2
- Condition identifier
- HP_0001337
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0003233
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005027
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005090
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005180
- Highest recorded phase
- 2
- NCT00827918
- NCT03101241
- NCT05122650
- NCT03406702
- Hydrogen bond acceptors
- 3
- Hydrogen bond donors
- 1
- Polar surface area
- 51.22
- Calculated partition coefficient (ALogP)
- 4.57
- Calculated partition coefficient (XLogP)
- 4.2
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 7
- Heavy atoms
- 27
- Molecular formula
- C20H23F3N2O2
- Monoisotopic mass
- 380.17116247
- Natural product
- No
- Recorded assays
- 333
- Active assays
- 52
Active assay types
- Confirmatory
Cardiac potassium channel inhibition
- Median
- 6,350
- Mean
- 6,350
- Minimum
- 4,000
- Maximum
- 8,700
- Unit
- nM
- Assays
- 2
- Standard deviation
- 3,323.4
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- IC50
Oral bioavailability
- Median
- 27.5
- Mean
- 31.8
- Minimum
- 2.8
- Maximum
- 76
- Unit
- %
- Assays
- 6
- Standard deviation
- 28.1368
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Plasma protein binding
- Median
- 99.4
- Mean
- 99.325
- Minimum
- 98.8
- Maximum
- 99.7
- Unit
- %
- Assays
- 4
- Standard deviation
- 0.411299
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- PPB
Related records
Trials (6)
- A Phase 2 RCT Study of CX-8998 for Essential Tremor
- A Phase 2 Study of CX-8998 in Adults With Tremor Associated With Parkinson's Disease
- A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease
- A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)
- A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004)
- CX-8998 for Absence Seizures
In development for (4)
- Epilepsy Phase 2
- Essential tremor Phase 2
- Parkinson disease Phase 2
- Schizophrenia Phase 2